### **Overview** Wockhardt Limited is a global, research-driven pharmaceutical and biotechnology company headquartered in Mumbai, India. With over 27 years of dedicated focus on innovation, the company specializes in addressing unmet medical needs in **antibiotic resistance** and **chronic disease management**, particularly in diabetes. Wockhardt operates in more than 40 countries with a strong international footprint, supported by manufacturing and R&D facilities in India, the United Kingdom, Ireland, and partnerships across Europe, Latin America, and Asia. Approximately **76–79% of its global revenue** is derived from international markets, with significant contributions from the UK, EU, Ireland, emerging markets, and selective presence in the US. The company employs nearly **2,900 people from 27 nationalities**, reflecting its global workforce and cross-border operational scale. --- ### **Strategic Focus Areas (2025 Outlook)** Wockhardt has restructured its business strategy to focus on two high-growth, innovation-led segments: 1. **Novel Antibiotic Development (Anti-Infectives)** 2. **Diabetes Biosimilars and Biobetters** The company has exited unprofitable segments—such as its US generic pharmaceutical operations—to redirect capital and R&D resources toward these advanced, differentiated therapies with higher long-term value potential. --- ### **Key Business Segments** #### **1. Antibiotic Innovation & New Chemical Entities (NCEs)** Wockhardt is globally recognized as **the only pharmaceutical company with six antibacterial discovery programs awarded Qualified Infectious Disease Product (QIDP) status by the U.S. FDA**—three targeting **Gram-negative** and three **Gram-positive** pathogens. This portfolio addresses the growing threat of antimicrobial resistance (AMR), projected to cause up to **8 million deaths annually by 2050**. ##### **Pipeline Highlights (as of Nov 2025):** - **Zidebactam-Cefepime (WCK 5222 / ZAYNICH®)** - A first-in-class **β-lactam enhancer** combination for treating **multi-drug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative infections**, including pathogens with NDM and KPC carbapenemases. - Demonstrated **96.8% clinical cure rate** in a global Phase III trial (ENHANCE 1) for complicated urinary tract infections (cUTI), significantly outperforming meropenem (68.4%). - Achieved **Breakthrough Medicine designation in Saudi Arabia** and **Fast Track + QIDP status from the U.S. FDA**. - **New Drug Application (NDA)** submitted to the U.S. FDA and India’s DCGI. - Compassionate use in **over 50 critically ill patients** (including in the U.S.) showed >95% cure rates and excellent safety across severe infections (e.g., meningitis, chronic abscesses). - Under compassionate use, **30 patients with no other treatment options were successfully treated, saving 30 lives**. - Positioned to target a **global addressable market of ~$9 billion** in the U.S., EU, and India, with an estimated **2 million eligible patients**. - **MIQNAF® (Nafithromycin / WCK 4873)** - A novel **macrolide-class oral antibiotic**, the **first new respiratory antibiotic developed in India in over 30 years**. - Approved in India for **community-acquired bacterial pneumonia (CABP)**; **launched in May 2025**. - Offers a **3-day, once-daily, ultra-short-course regimen** with **97% cure rate**, outperforming older therapies facing >60% resistance (e.g., azithromycin). - **QIDP status** from U.S. FDA and **Breakthrough Medicinal Product (BMP)** status in Saudi Arabia, where an NDA has been filed. - Targets an **India addressable market of ~₹10,800 crores**, with expansion plans to **Latin America, Africa, Southeast Asia, and GCC countries**. - Received **BIRAC Innovator Award 2024** from the Indian government. - **Foviscu (WCK 4282)** - In a **combined Phase 2/3 trial** for cUTI, designed as a novel alternative to piperacillin/tazobactam. - No serious adverse events reported in Phase 2; supports potential de-escalation of carbapenem use. - **WCK 6777 (Ertapenem-Zidebactam)** - A once-daily **outpatient parenteral antibiotic therapy (OPAT)** candidate for treating MDR infections in ambulatory settings. - **Fast Track designation** from U.S. FDA for cUTI and cIAI. - Phase I study conducted by the **U.S. National Institutes of Health (NIH)** confirmed a favorable safety profile. - Could reduce hospital stays, lower costs, and enable home-based treatment. ##### **R&D Capabilities** - Dedicated team of **over 145 scientists**, including **50 with PhDs**. - End-to-end capabilities in drug discovery, clinical development, and regulatory execution. - **108 biotech patents filed globally**; **47 patents in biosimilars and bio-betters**, including **23 for insulin pen technology**. - Over **3,273 cumulative patent filings** and **848 granted patents** as of March 2025. --- #### **2. Diabetes Biosimilars & Biobetters** Wockhardt is emerging as a key player in the global diabetes biosimilars market, with a vertically integrated platform spanning **R&D, API, formulation, and drug delivery devices**. ##### **Key Products & Pipeline** - **ASPARAPID™ (Aspart Insulin)** - **Indigenously developed fast-acting insulin analog**; dossier filed with India’s DCGI. - Available in vials, cartridges, and pre-filled pens. - Addresses a **$1.5 billion Indian insulin market**, with Aspart segment worth ~$700 million. - **Glaritus® (Insulin Glargine)** - Commercially available in India and emerging markets; expanding into Latin America and GCC. - **Insulin Aspart R & Mix, Lispro R, and WCK 9406** - WCK 9406 is a **proprietary bio-better combination** of fast-acting and long-acting insulin analogs in development. ##### **Delivery Devices** - Proprietary **Dispopen® (disposable) and Mypen® (reusable)** insulin pens, with **second-generation models** launched in 2019 and 2023. - **Next-gen pens under development**; **two global patents protecting pen technology**. - Positioned to capture the **INR 450 crore (~$157 million) market opportunity** created by **Novo Nordisk’s exit** from human insulin pens and cartridges. ##### **Manufacturing & Infrastructure** - Integrated platform using **E. coli, yeast, and mammalian cell expression systems**. - Four drug substance production blocks and **three drug product facilities** (two in India, one in UK). - **Scalable API production**: current capacity of ~3 tons/year, expandable to **>6 tons with DSP upgrades**. - Clinical Pharmacokinetics & Biopharmaceutics (CPB) unit in India: **76-bed facility**, glucose clamp capability, **approved by FDA, MHRA, ANVISA, and CDSCO**. --- ### **Global Operations & Commercial Strategy** - **Manufacturing & R&D Sites**: India (Mumbai, Aurangabad), UK (Wrexham), Ireland. - **Major Markets**: - **UK**: Contributes ~38–41% of global revenue; top 3 Indian generic supplier; 6th largest in hospital and retail segments. - **Ireland**: €10 million+ in revenue; strong branded generics and OTC presence. - **Emerging Markets**: 24–26% of revenue; growth focus on GCC, Latin America, Africa, and Southeast Asia. - **US**: Restructured to contract manufacturing; strategic focus shifting to **independent commercialization or outlicensing** for WCK 5222. - **UK Subsidiary**: Wockhardt UK Holdings Limited (100% owned). --- ### **Corporate Restructuring & Innovation Strategy** - **Exited US Generics**: Due to sustained losses (~$8 million in FY25), shifted to **third-party contract manufacturing** with **~40% gross margins**. - **Debt & Capital Structure**: - Raised **₹1,000 crore via QIP** to fund clinical trials and reduce leverage. - Prioritized **debt reduction, cost containment, working capital optimization**. - **Vaccine Manufacturing**: Partnership with **Serum Life Sciences UK** for **150 million annual vaccine doses** (profit-sharing JV); expanding into **non-COVID vaccines**.